These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1617 related items for PubMed ID: 28057031

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.
    Cancer; 2008 Mar 01; 112(5):995-1000. PubMed ID: 18098228
    [Abstract] [Full Text] [Related]

  • 5. The correlation of 18F-FDG PET/CT metabolic parameters, clinicopathological factors, and prognosis in breast cancer.
    Qu YH, Long N, Ran C, Sun J.
    Clin Transl Oncol; 2021 Mar 01; 23(3):620-627. PubMed ID: 32683540
    [Abstract] [Full Text] [Related]

  • 6. Metabolic Tumor Burden Assessed by Dual Time Point [18F]FDG PET/CT in Locally Advanced Breast Cancer: Relation with Tumor Biology.
    Garcia-Vicente AM, Pérez-Beteta J, Pérez-García VM, Molina D, Jiménez-Londoño GA, Soriano-Castrejón A, Martínez-González A.
    Mol Imaging Biol; 2017 Aug 01; 19(4):636-644. PubMed ID: 27981471
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients.
    Lemarignier C, Martineau A, Teixeira L, Vercellino L, Espié M, Merlet P, Groheux D.
    Eur J Nucl Med Mol Imaging; 2017 Jul 01; 44(7):1145-1154. PubMed ID: 28188325
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
    Groheux D, Hatt M, Hindié E, Giacchetti S, de Cremoux P, Lehmann-Che J, Martineau A, Marty M, Cuvier C, Cheze-Le Rest C, de Roquancourt A, Visvikis D, Espié M.
    Cancer; 2013 Jun 01; 119(11):1960-8. PubMed ID: 23504954
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
    Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC.
    Oncologist; 2017 May 01; 22(5):526-534. PubMed ID: 28377466
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Harmonized pretreatment quantitative volume-based 18F-FDG PET/CT parameters for stage IV breast cancer prognosis. Multicenter study in Japan.
    Kitajima K, Miyoshi Y, Sekine T, Takei H, Ito K, Suto A, Kaida H, Daisaki H, Yamakado K.
    Hell J Nucl Med; 2020 May 01; 23(3):272-289. PubMed ID: 33367302
    [Abstract] [Full Text] [Related]

  • 16. Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma.
    Jung NY, Kim SH, Choi BB, Kim SH, Sung MS.
    World J Surg Oncol; 2015 Mar 15; 13():113. PubMed ID: 25889560
    [Abstract] [Full Text] [Related]

  • 17. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S, Tanriverdi O, Karapolat I, Demir L, Bayoglu V, Can A, Akyol M, Yilmaz Y, Oktay Tarhan M.
    J BUON; 2016 Mar 15; 21(6):1410-1418. PubMed ID: 28039701
    [Abstract] [Full Text] [Related]

  • 18. Textural features of 18F-FDG PET after two cycles of neoadjuvant chemotherapy can predict pCR in patients with locally advanced breast cancer.
    Cheng L, Zhang J, Wang Y, Xu X, Zhang Y, Zhang Y, Liu G, Cheng J.
    Ann Nucl Med; 2017 Aug 15; 31(7):544-552. PubMed ID: 28646331
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. 18F-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer.
    Ulaner GA, Castillo R, Wills J, Gönen M, Goldman DA.
    Eur J Nucl Med Mol Imaging; 2017 Aug 15; 44(9):1420-1427. PubMed ID: 28456837
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 81.